 <h1>Estradiol / norethindrone topical Side Effects</h1><ul class="nav-tabs nav-tabs-collapse nav-tabs-pill">
<li><b class="nav-item here">Side Effects</b></li>
<li>Interactions</li>
<li>Pregnancy</li>
<li class="nav-more">
More&lt;svg aria-hidden="true" class="ddc-icon ddc-icon-down" focusable="false" height="16" viewbox="0 0 24 24" width="16" xmlns="http://www.w3.org/2000/svg"&gt;&lt;path d="M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z"&gt;&lt;/path&gt;&lt;/svg&gt;
</li>
</ul><ul>
<li>Managing Side Effects</li>
</ul><p><i>Applies to estradiol/norethindrone topical: topical film extended release</i></p><h3>Genitourinary</h3><p>Genitourinary side effects including breast pain (25% to 31%), dysmenorrhea (20% to 21%), vaginitis (6% to 13%), menstrual disorder (6% to 12%), suspicious Papanicolaou smear (4% to 8%), and leukorrhea (5%).  Postmarketing side effects include endometrial hyperplasia, endocervical polyp, uterine leiomyomata, fallopian tube cyst, uterine spasms, and breast cancer.<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Respiratory side effects including rhinitis (7% to 13%), respiratory disorder (7% to 12%), pharyngitis (4% to 10%), and sinusitis (4% to 9%) were reported.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Gastrointestinal side effects including nausea (8% to 11%), abdominal pain (6% to 7%), diarrhea (4% to 5%), flatulence (4% to 5%), and dyspepsia (1% to 5%) were reported.<sup>[Ref]</sup></p><h3>Local</h3><p>Local side effects including reaction at the application site (2% to 6%) has been reported.<sup>[Ref]</sup></p><h3>General</h3><p>General side effects including headache (18% to 20%), asthenia (8% to 12%), back pain (9% to 11%), flu syndrome (5% to 9%), pain (4% to 6%), and accidental injury (4% to 5%) have been reported.  Postmarketing side effects include increased weight.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Psychiatric side effects including nervousness (3% to 6%) and depression (3% to 6%) have been reported.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Hypersensitivity side effects include postmarketing reports of angioedema and hypersensitivity.</p><h3>Cardiovascular</h3><p>Cardiovascular side effects include postmarketing reports of hypertension and varicose veins.</p><h3>Dermatologic</h3><p>Dermatologic side effects include postmarketing reports of skin discoloration.</p><h3>Hepatic</h3><p>Hepatic side effects include postmarketing reports of jaundice cholestatic, cholelithiasis, gall bladder disorder, and increased transaminases.</p><h3>Nervous system</h3><p>Nervous system side effects include postmarketing reports of affect lability, libido disorder, migraine, vertigo, and paraesthesia.</p><p id="ref_1">1. "Product Information. CombiPatch (estradiol-norethindrone topical)." Rhone-Poulenc Rorer, Collegeville, PA. </p><h2>More about estradiol / norethindrone topical</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Drug Interactions</li>
<li>Drug class: sex hormone combinations</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>